Upstream markers provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes

被引:11
作者
Kavsak, Peter A.
Ko, Dennis T.
Newman, Alice M.
Palomaki, Glenn E.
Lustig, Viliam
MacRae, Andrew R.
Jaffe, Allan S.
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[2] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON M5S 1A3, Canada
[3] Women & Infants Hosp Rhode Isl, Dept Pathol, Providence, RI USA
[4] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[5] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada
[6] Mayo Clin, Div Lab Med, Div Cardiovasc, Rochester, MN USA
关键词
acute coronary syndrome; myocardial necrosis; biomarker panel; outcomes;
D O I
10.1016/j.cca.2007.09.023
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: For patients presenting with,acute coronary syndrome (ACS) to the emergency department, early identification of those that are at high risk for subsequent myocardial necrosis or adverse outcomes would allow earlier or more aggressive treatment. We determined if a panel of biomarkers can be used to identify high risk patients. Methods: A cohort (84 females/132 males) from our 1996 ACS study population that had EDTA specimens stored (-70 degrees C) was selected and the earliest available specimen was analyzed for 11 biomarkers (IL-6, IL-8, MCP-1, VEGF, L-selectin, P-selectin, E-selectin, ICAM-1, VCAM-1, NTproBNP, cTnT). These data were linked to the existing cTnI and health outcome databases for this population. ROC curve analysis for myocardial necrosis (i.e., peak cTnI > 0.04 mu g/l) identified 3 candidate biomarkers. These 3 biomarkers were applied together to generate a panel test (2 of the 3 biomarkers increased for a positive result) and assessed for its ability to identify patients at risk for myocardial necrosis and the combined endpoint of death, myocardial infarction (MI) and heart failure (HF). Results: The panel test (IL-6, NT-proBNP, E-selectin) alone detected 60% (95% CI: 49-69; false positive rate: 26%) of subjects that would be classified with myocardial necrosis. Kaplan-Meier and Cox proportional analyses indicated that patients positive by the biomarker panel (including those with cTnI <= 0.04 mu g/l) had significantly worse outcomes (deatb/MI/HF) as compared to those negative by both cTnI and the panel test. Conclusion: A biomarker panel analyzed early after pain onset can identify individuals at risk for both myocardial necrosis and the combined endpoint of death/MI/HF. Additional prospective studies are required to assess this panel for both early MI detection and to further refine which health outcomes (death, MI, HF) are associated with positive panel results. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 27 条
[1]   Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology American College of Cardiology consensus recommendations [J].
Apple, FS ;
Quist, HE ;
Doyle, PJ ;
Otto, AP ;
Murakami, MM .
CLINICAL CHEMISTRY, 2003, 49 (08) :1331-1336
[2]   Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome [J].
Apple, FS ;
Wu, AHB ;
Mair, J ;
Ravkilde, J ;
Panteghini, M ;
Tate, J ;
Pagani, F ;
Christenson, RH ;
Mockel, M ;
Danne, O ;
Jaffe, AS .
CLINICAL CHEMISTRY, 2005, 51 (05) :810-824
[3]   Interaction between chemokines and oxidative stress:: Possible pathogenic role in acute coronary syndromes [J].
Aukrust, P ;
Berge, RK ;
Ueland, T ;
Aaser, E ;
Damås, JK ;
Wikeby, L ;
Brunsvig, A ;
Müller, F ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :485-491
[4]   A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario [J].
Austin, PC ;
Daly, PA ;
Tu, JV .
AMERICAN HEART JOURNAL, 2002, 144 (02) :290-296
[5]   Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort [J].
Berrahmoune, H ;
Lamont, JV ;
Herbeth, B ;
FitzGerald, P ;
Visvikis-Siest, S .
CLINICAL CHEMISTRY, 2006, 52 (03) :504-510
[6]   C-reactive protein and other inflammatory risk markers in acute coronary syndromes [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :37S-42S
[7]  
BLANKENBERG S, 2006, CIRCULATION, V114
[8]   Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Sabatine, MS ;
Murphy, SA ;
Gibson, CM ;
Antman, EM ;
McCabe, CH ;
Cannon, CP ;
Braunwald, E .
CIRCULATION, 2003, 107 (05) :690-695
[9]   Sites of interleukin-16 release in patients with acute coronary syndromes and in patients with congestive heart failure [J].
Deliargyris, EN ;
Raymond, RJ ;
Theoharides, TC ;
Boucher, WS ;
Tate, DA ;
Dehmer, GJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (09) :913-918
[10]   Pregancy-associated plasma protein-a levels in patients with acute coronary syndromes - Comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis [J].
Heeschen, C ;
Dimmeler, S ;
Hamm, CW ;
Fichtscherer, S ;
Simoons, ML ;
Zeiher, AM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :229-237